To increase BCR/ABL inhibitory activity in CML cells, hybrid compounds including portions of the structures of imatinib, nilotinib, and dasatinib have been created [92]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.